RN624 In Adult Patients With Chronic Low Back Pain

NCT ID: NCT00584870

Last Updated: 2021-07-12

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-07-05

Study Completion Date

2008-09-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate the analgesic efficacy of RN624 compared with placebo and compared with naproxen in the treatment of adult patients with chronic low back pain.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Low Back Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Naproxen

Group Type ACTIVE_COMPARATOR

Naproxen

Intervention Type DRUG

Oral naproxen 500 mg twice daily for Weeks 1-12.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Single IV infusion of placebo on Day 1 and placebo for naproxen twice daily for Weeks 1-12.

RN624

Group Type EXPERIMENTAL

PF-04383119 (RN624)

Intervention Type DRUG

Single IV infusion of 200 micrograms/kg RN624 on Day 1

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Naproxen

Oral naproxen 500 mg twice daily for Weeks 1-12.

Intervention Type DRUG

Placebo

Single IV infusion of placebo on Day 1 and placebo for naproxen twice daily for Weeks 1-12.

Intervention Type DRUG

PF-04383119 (RN624)

Single IV infusion of 200 micrograms/kg RN624 on Day 1

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female of any race, \>18 years of age and have BMI ≤39 kg/m2
* Present with duration of chronic low back pain of ≥3 months requiring regular use of analgesic medication (\>4 days per week for the past month)
* Primary location of low back pain is between the 12th thoracic vertebra and the lower gluteal folds, with or without radiation into the posterior thigh, classified as Category 1 or 2 according to the classification of the Quebec Task Force in Spinal Disorders
* Must have a score of ≥4 for Low Back Pain Intensity (NRS) while on current treatment at Screening, and completes at least 4 daily pain diaries during the 5 days prior to Randomization, with an average Low Back Pain Intensity (NRS) score of ≥4

Exclusion Criteria

* Back pain due to visceral disorder (i.e. endometriosis) or Back pain due to recent major trauma (i.e. vertebral fracture, post-traumatic spondylolisthesis)
* History of lumbosacral radiculopathy, spinal stenosis associated with neurological impairment, or neurogenic claudication
* Osteoporotic compression fracture within the last 6 months
* Known history of: Rheumatoid arthritis; Seronegative spondyloarthropathy (i.e., ankylosing spondylitis, psoriatic arthritis, reactive arthritis, inflammatory bowel disease-related arthropathy); Paget's disease of spine, pelvis or femur; Fibromyalgia; Tumors or infections of the spinal cord
* Patients receiving acetaminophen only to manage their chronic low back pain
* Any uncontrolled or untreated chronic disease
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Radiant Research

Scottsdale, Arizona, United States

Site Status

Pinnacle Research Group LLC

Anniston, Alabama, United States

Site Status

Radiant Research

Birmingham, Alabama, United States

Site Status

Radiant Research - Phoenix Southeast

Chandler, Arizona, United States

Site Status

Advanced Clinical Research Institute

Anaheim, California, United States

Site Status

University of California San Diego

San Diego, California, United States

Site Status

Doctors Medical Center of Walton County

DeFuniak Springs, Florida, United States

Site Status

SJS Clinical Research, Inc.

Destin, Florida, United States

Site Status

Adult Medicine Specialists

Longwood, Florida, United States

Site Status

Genesis Research International

Longwood, Florida, United States

Site Status

Collier Neurologic Specialists

Naples, Florida, United States

Site Status

Cotton-O'Neil Clinical Research

Topeka, Kansas, United States

Site Status

Cotton-O'Neil Clinic

Topeka, Kansas, United States

Site Status

Heartland Research Associates

Wichita, Kansas, United States

Site Status

Northeast Medical Research Associates, Inc

North Dartmouth, Massachusetts, United States

Site Status

Clinical Pharmacology Study Group

Worcester, Massachusetts, United States

Site Status

Spence Medical Research

Picayune, Mississippi, United States

Site Status

Radiant Research, Inc.

St Louis, Missouri, United States

Site Status

Quality Clinical Research, Inc.

Omaha, Nebraska, United States

Site Status

The Medical Research Network, LLC

New York, New York, United States

Site Status

North State Clinical Research, PLLC

Lenoir, North Carolina, United States

Site Status

Wake Internal Medicine Consultants, Inc.

Raleigh, North Carolina, United States

Site Status

Wake Research Associates

Raleigh, North Carolina, United States

Site Status

Summit Research Network (Oregon), Inc.

Portland, Oregon, United States

Site Status

Allegheny Pain Management

Altoona, Pennsylvania, United States

Site Status

New England Center for Clinical Research

Cranston, Rhode Island, United States

Site Status

Partners in Clinical Research

Cumberland, Rhode Island, United States

Site Status

Omega Medical Research

Warwick, Rhode Island, United States

Site Status

Radiant Research

Greer, South Carolina, United States

Site Status

Advanced Therapeutics, Inc.

Johnson City, Tennessee, United States

Site Status

Johnson City Internal Medicine

Johnson City, Tennessee, United States

Site Status

DiscoveResearch, Incorporated

Bryan, Texas, United States

Site Status

Advances In Health, Inc.

Houston, Texas, United States

Site Status

Centex Research

Nassau Bay, Texas, United States

Site Status

Immediate Medical Care

Nassau Bay, Texas, United States

Site Status

Radiant Research San Antonio

San Antonio, Texas, United States

Site Status

Independence Family Medicine

Virginia Beach, Virginia, United States

Site Status

Summit Research Network (Seattle) LLC

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLBP POC

Identifier Type: OTHER

Identifier Source: secondary_id

A4091004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

NSAIDs in Sciatica NSAIDS IN SCIATICA
NCT03347929 COMPLETED PHASE4
Actual Use Trial of Naproxen Sodium
NCT01427803 COMPLETED PHASE3
Self Selection Trial of Naproxen Sodium
NCT01383486 COMPLETED PHASE3